Skip to main content

Ariadna Laguna Tuset

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
I received my Biology degree, Health and Life Sciences specialization, in 2003 at the Universitat Pompeu Fabra (Barcelona, Spain). I got my Ph.D. in 2008 in the laboratory of Dr. Mariona Arbonés at the Center for Genomic Regulation (CRG, Barcelona, Spain). My Ph.D. was devoted to study the molecular basis of Down Syndrome neurological alterations. In 2009, I joined the group of Professor Thomas Perlmann at the Ludwig Institute for Cancer Research – Karolinska Institutet (Stockholm, Sweden) as a post-doctoral Marie Curie researcher to work on the transcriptional regulation of dopamine neurons during development and in pathological conditions such as Parkinson’s disease.

In 2014, I moved back to Barcelona and joined the Neurodegenerative Diseases Research Group at the Vall d’Hebron Research Institute (VHIR) as a Beatriu de Pinós post-doctoral researcher funded by AGAUR-FP7 Marie Curie Actions. Afterwards, I received a Young Investigator contract from the Spanish government (Ministry of Economy and Competitiveness (MINECO)) and a Junior Leader fellowship from the La Caixa Foundation to establish my own research lines within the group. In addition, I am an associate researcher at the Neuroscience Institute of the Autonomous University of Barcelona (UAB) and Scientific Ambassador of the World Parkinson Coalition.

The research from my team is devoted to elucidate the molecular mechanisms of inter-organ communication in Parkinson’s disease and how this contributes to the pathophysiology and symptoms of this neurodegenerative disorder. Our research contributes to: (i) identify biomarkers for early detection, disease progression or response to treatment, (ii) identify new molecular targets and develop novel therapeutic strategies with disease-modifying potential, (iii) unravel molecular pathways common to other neurodegenerative or metabolic diseases. Researcher ID: F-9561-2016; Orcid: 0000-0002-9732-6677.

Research lines

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Miquel Vila Bover, Ariadna Laguna Tuset

Projects

El eje cerebro-cuerpo en la enfermedad de Parkinson: de la fisiopatología a los biomarcadores y enfoques terapéuticos.

IP: Ariadna Laguna Tuset
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 219250
Reference: RYC2021-032947-I
Duration: -

Ministerio de Ciencia

The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI21/01603
Duration: 01/01/2022 - 31/12/2024

The Gut-Brain axis in Parkinson's disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: -
Funding agency: Fundació "La Caixa"
Funding: 299700.09
Reference: 2018_INCOMING_CAIXA/LAGUNA
Duration: 02/10/2019 - 02/10/2022

El eje Intestino-Cerebro en la fase prodrómica de la Enfermedad de Parkinson: nuevas posibilidades para el desarrollo de biomarcadores de riesgo/diagnóstico y de intervenciones terapéuticas.

IP: Ariadna Laguna Tuset
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 205700
Reference: SAF2015-73997-JIN
Duration: 01/12/2016 - 20/03/2020

Related news

Es tracta del projecte “New Nanotechnological Therapy for Parkinson’s disease: Nose to Brain Delivery of GBA-Polymer Nanoconjugates (nanoGBAtoBrain)”.

La primera jornada dedicada a aquesta malaltia organitzada pel Campus Vall d’Hebron ha reunit més de 150 assistents.

As of tomorrow, Lleida will be hosting the 19th Congress of the Spanish Society of Neuroscience (SENC). This is a biennial event, which this year will be held from 3 to 5 November in la Llotja, the Lleida Exhibition Centre.

Related professionals

Anna Garcia Serra

Anna Garcia Serra

Neurodegenerative Diseases
Read more
Maria Sellés Altés

Maria Sellés Altés

Research technician
Neurodegenerative Diseases
Read more
Marina Lorente Picón

Marina Lorente Picón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Roman Serrat  Reñe

Roman Serrat Reñe

Postdoctoral researcher
Neurodegenerative Diseases
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.